Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
The University of Texas MD Anderson Cancer Center · Moffitt Cancer Center · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,357
total citations
- FWCI
- 86.34
- Percentile
- 100%
- References
- 100
Citations per year
Authors
19- SSSattva S. NeelapuCorresponding
The University of Texas MD Anderson Cancer Center
- STSudhakar Tummala
The University of Texas MD Anderson Cancer Center
- PKPartow Kebriaei
The University of Texas MD Anderson Cancer Center
- WGWilliam G. Wierda
The University of Texas MD Anderson Cancer Center
- CGCristina Gutiérrez
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Chimeric antigen receptor
- Medicine
- Cytokine release syndrome
- Immunotherapy
- Immunology
- Encephalopathy
- Internal medicine
- Immune system
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BSBristol-Myers Squibb
- ELEli Lilly and CompanyAward: P30 CA016672
- PPfizer
- AAstraZenecaAward: CA016672
- SSanofi
- GSGilead Sciences
- CCelgene
- CTCelldex Therapeutics
- SSunesis
- FPFive Prime Therapeutics
- ABAdaptive Biotechnologies
- DPDeciphera Pharmaceuticals
- IIncyteAward: CA016672
- KPKiadis Pharma
- SServier
- NINational Institutes of HealthAwards: CA016672, P30 CA016672
- GGenentech
- UOUniversity of Texas MD Anderson Cancer CenterAwards: CA016672, P30 CA016672
- KPKite Pharma
- PPharmacyclics
- JTJuno Therapeutics
- FMFoundation Medicine